Two private equity giants are reportedly discussing launching a joint bid for the generics unit of pharma giant Novartis, according to reports.
Blackstone and Carlyle Group have discussed teaming up to launch a bid for the Sandoz generics arm of the Swiss drugmaker which could be valued at $25bn (£18.5bn), Bloomberg reported.
Sandoz generated $9.7 billion in sales last year and German news outlet Handelsblat reported in November that the arm was on sale for of $21.6 billion.
Read more: City AM
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.